Skip to main
NVS
NVS logo

Novartis (NVS) Stock Forecast & Price Target

Novartis (NVS) Analyst Ratings

Based on 2 analyst ratings
Sell
Strong Buy 0%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 50%

Bulls say

Novartis demonstrates a robust outlook supported by the strong performance of its key drug Cosentyx, which achieved 25% year-over-year growth due to successful label expansions and market uptake. The firm has raised its 2024 financial outlook, indicating positive sales trends across multiple therapeutic areas, with potential for further growth stemming from unmodeled pipeline assets that may prove clinically effective. Additionally, the long lifecycle and targeted approach of Scemblix, alongside the promising revenue potential from other therapies, position Novartis favorably for continued financial success.

Bears say

The negative outlook on Novartis's stock is influenced by concerns regarding the clinical viability of its late-stage assets, which, if proven unviable, could exert downward pressure on share prices. Furthermore, any shortfalls in sales relative to projections or consensus estimates may lead to additional negative impacts on stock value. Additionally, potential delays or rejections in the approval process for new pipeline assets and label-expanding initiatives could adversely affect future cash flow and overall valuation, compounded by external factors such as unfavorable policy developments or economic downturns.

Novartis (NVS) has been analyzed by 2 analysts, with a consensus rating of Sell. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 50% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novartis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novartis (NVS) Forecast

Analysts have given Novartis (NVS) a Sell based on their latest research and market trends.

According to 2 analysts, Novartis (NVS) has a Sell consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $119, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $119, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novartis (NVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.